No Data
No Data
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Biocytogen Pharmaceuticals' Loss Narrows in 2023
Biocytogen Pharmaceuticals (Beijing) (HKG:2315) cut its losses to roughly 383 million yuan in 2023 from nearly 602.2 million yuan in the preceding year, according to a Thursday filing with the Hong Ko
百奧賽圖-B:2023年度報告
Featured announcements | Shandong Gold's Q1 net profit is expected to increase by 48.11% to 70.9% year-on-year
Xinji Shaxi: 14.16% of the company's shares held by the controlling shareholder were forcibly sold, and trading resumed today; express sales: net profit of 195.9 billion yen in the first half of the year, up 27.7% year on year; Smore International: profit after tax for the first quarter was about 339.5 million yuan, up 12.8% year on year.
Biosetu-B (02315.HK) is expected to approach the break-even point in 2024 and plans to make further share purchases of no more than HK$10 million
Gelonghui announced on April 11 | Biosetu-B (02315.HK) announced that the company noticed unusual fluctuations in the stock price of the company's shares listed on the Hong Kong Stock Exchange Limited recently. The company hereby explains that there have been no major adverse events in its production and operation activities, and that all business lines have maintained steady growth and are progressing steadily in accordance with the established strategy. The company's board of directors and management team are confident in the company's development prospects and do not expect any significant adverse changes in the company's production and operation activities and financial situation. As disclosed in the overseas regulatory announcement on January 5, 2024, according to the company's careful calculations, the company is expected to reach 20
Baiaosetu (2315.HK) 2023 review: Overseas revenue is growing rapidly, Qianmu Wanbang has completed phased R&D, and the self-research pipeline is successfully authorized and transferred to the outside world
Incident The company announced 2023 results: in 2023, revenue of 717 million yuan (+34%), overseas revenue of 408 million yuan (+66%), gross margin of 70.6% (+2.8pp), net profit loss
No Data